The Global Antibiotic Resistance Market is driven by rising prevalence of infectious diseases

Comments ยท 6 Views

The Global Antibiotic Resistance Market is estimated to be valued at US$ 8.83 BN in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period 2024 to 2031.

The Global Antibiotic Resistance Market comprises therapeutics used to treat infections caused by antibiotic-resistant microorganisms. Antibiotic resistance occurs when bacteria change over time and become insensitive to medications, especially antibiotics, which are used to treat infections. Increasing prevalence of infectious diseases including pneumonia, tuberculosis, gonorrhea, salmonellosis, and staphylococcal infections are driving the demand for effective anti-infective drugs. Limited pipeline of new antibiotics and increasing investment in R&D are further fueling the market growth.

The Global Antibiotic Resistance Market is estimated to be valued at US$ 8.83 BN in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Global Antibiotic Resistance Market Growth are Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceuticals, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, and NEMESIS BIOSCIENCE LTD. These players are actively investing in developing novel antibiotics and combination therapies to treat drug-resistant infections.

The growing prevalence of communicable diseases around the world is driving the demand for effective anti-infective treatments. According to the WHO, antibiotic resistance is one of the biggest threats to global health, food security, and development today. Failure to treat infectious diseases can jeopardize cancer treatment and major surgery success as well as the care of preterm babies. It can impact anyone, of any age, in any country.

Key players are focusing on expanding their global footprint through acquisitions and collaboration with regional players. Companies are engaged in developing a broad pipeline of antibacterial candidates with novel mechanisms of action to treat serious and life-threatening multi-drug resistant infections lacking adequate treatment options. This is expected to further fuel market growth during the forecast period.

Market drivers

The increasing usage and sometimes misuse of antibiotics is a key factor contributing to the rising antibiotic resistance worldwide. When misused, antibiotics can promote the growth of drug-resistant microorganisms. Furthermore, limited investment in developing new antibiotics is also fueling the market. Pharmaceutical companies are actively focusing on R&D to develop novel combination therapies and antibacterial candidates with innovative mechanisms of action to effectively treat multi-drug resistant bacterial infections. This is expected to provide lucrative opportunities for market players over the forecast period.

Current Geopolitical Situation and Impact on Global Antibiotic Resistance Market Growth

The current geopolitical tensions have highlighted the vulnerability of global supply chains and dependence on international trade. This is having a profound impact on the antibiotic resistance market. Heightened geopolitical risks threaten to disrupt the supply of key antibiotics and active pharmaceutical ingredients. Several major producers of APIs are based in regions witnessing conflicts or international sanctions. Any disturbances in trade flows from these countries can significantly impact the availability and affordability of life-saving antibiotics globally. Furthermore, funding for research and development of new antibiotics has reduced amid economic uncertainties caused by geopolitical issues. Developing alternative manufacturing capacities and diversifying API sourcing have become strategic priorities for key players. However, the large capital investments and long development timelines pose challenges. Public-private partnerships and coordination between nations will be crucial to build resilience into global antibiotic supply chains and incentivize continued innovation.


Get more insights on Global Antibiotic Resistance Market  

Comments